Global private equity and venture capital news and research

Abingworth closes sixth fund above target

26 Feb 2014

life science test tube_sqUK life sciences-focused firm Abingworth Management is reportedly nearing a final close for its sixth fund, which has been oversubscribed.

Abingworth Bioventures VI is set to close on £225m, ahead of its £200m initial target, said Dow Jones, citing a person close to the effort.

Back in October AltAssets reported that Abingworth had raised £205.5m from 31 LPs.

Abingworth provides venture and growth capital and invests in publicly listed companies in the life sciences and healthcare sectors, making minority and majority deals valued at between $20m and $80m.

The firm has invested in more than 100 life sciences companies, third of which have been acquired or have gone public.

Abingworth’s investees include Menlo Park-based startup Personalis, which provides medical exome and genome sequencing and interpretation services.

Copyright © 2014 AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016